Cheng‐Pang Hsu
Amgen (United States)(US)Bridge Pharma (United States)(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Biosimilars and Bioanalytical Methods, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Analytical Chemistry and Chromatography
Most-Cited Works
- → Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis(2001)91 cited
- → A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer(2013)71 cited
- → Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma(2019)67 cited
- → TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer(2013)65 cited
- → Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape(2015)51 cited
- → Use of Classification Regression Tree in Predicting Oral Absorption in Humans(2004)46 cited
- → Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective(2017)27 cited
- → Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper(2022)19 cited
- → Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab(2022)19 cited
- → Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer(2015)14 cited